PHARMACOLOGICALLY ACTIVE HETEROCYCLIC-SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES

Patent metadata

Field	Value
Publication number	US-2023286988-A1
Application number	US-202118040456-A
Country	US
Kind code	A1
Filing date	Aug 5, 2021
Priority date	Aug 5, 2020
Publication date	Sep 14, 2023
Grant date	—

Abstract

The invention relates to new pyrazolo[1,5-a]pyrimidine derivatives of formula (I) or pharmaceutically acceptable salts, biologically active metabolites, pro-drugs, racemates, enantiomers, diastereomers, solvates and hydrates thereof that serve as GABAB receptor positive allosteric modulators. The invention also relates to the process for producing such compounds and key intermediates used in the process. The invention further relates to pharmaceutical compositions comprising such compounds optionally in combination with two or more different therapeutic agents and the use of such compounds in methods for treating diseases and conditions mediated and modulated by the GABAB receptor positive allosteric mechanism. The invention also provides a method for manufacture of medicaments useful in the treatment of such disorders.

First claim

1 . A compound of formula (I)

wherein
R 1 represents phenyl- or cyclohexyl group substituted by C 1 -C 6 alkyl or halo-C 1 -C 6 alkyl;
R 2 represents H or halogen;
R 3 represents H or C 1 -C 6 alkyl;
R 4 represents H; C 1 -C 6 alkyl or halo-C 1 -C 6 alkyl;
R 5 and R 6 may be each, independently H; C 1 -C 6 alkyl or halogen;
R 7 and R 8 may be each, independently H or C 1 -C 6 alkyl;
R 9 and R 10 may be each, independently H or C 1 -C 6 alkyl or R 9 and R 10 together may form oxo group;
X represents —CR x R y or —O— or —S(O) n — group, wherein R x and R y may be each, independently H or C 1 -C 6 alkyl group and wherein n is 0 or 1 or 2;
Z represents —NR—; or —O—; or —S(O) 2 — group wherein
R may be H or —C(O)R 11 or —S(O) 2 R 12 group; aminocarbonyl-C 1 -C 3 alkyl; carboxy-C 1 -C 3 alkyl; cyano-C 1 -C 3 alkyl; C 1 -C 5 (cyclo)alkyl; saturated 4-6 membered heterocyclic ring with one 0, or —C(NH)(NH 2 ) group;
wherein R 11 may be H; C 1 -C 3 alkyl; C 1 -C 3 alkoxy; deutero-C 1 -C 3 alkoxy; C 1 -C 3 alkoxy-C 1 -C 3 alkyl; C 1 -C 3 alkoxy-C 1 -C 3 alkoxy; methanesulphonyl-C 1 -C 3 alkyl; or R 11 may be a saturated 3-6 membered carbocyclic ring, or a 4-6 membered saturated or unsaturated heterocyclic ring with one to three hetero atoms selected from N, O or S; or amino, mono- or dialkylamino group; amino-C 1 -C 3 alkyl; hydroxy-C 1 -C 3 alkyl substituted by NH 2 -group;
wherein R 12 may be C 1 -C 3 alkyl; amino or dialkylamino group;
R 4 and CR x may form a cycloalkyl ring;
or pharmaceutically acceptable salts, biologically active metabolites, pro-drugs, racemates, enantiomers, diastereomers, solvates and hydrates thereof.

2 . A compound according to claim 1 wherein
if X represents —CR x R y then Z represents —NR— group; or
if X represents —O—; or —S(O)n-group then Z represents —NR— group; or
if X represents —CR x R y group then Z represents —O—; or —S(O) 2 — group.

3 . A compound according to claim 2 wherein X represents —CR x R y and Z represents —NR— group, wherein R may be —C(O)R 11 .

4 . A compound according to claim 2 wherein X represents —O— or —S(O) 2 — group and Z represents —NR— group, where R may be —C(O)R 11 or —S(O) 2 R 12 group.

5 . A compound according to claim 1 selected from the group of
1-[(3R)-3-{6-ethyl-5-methyl-2-[trans-4-(trifluoromethyl)cyclohexyl]pyrazolo[1,5-a]pyrimidin-7-yl}-3-methylpiperidin-1-yl]ethan-1-one,
1-[(3S)-3-{6-ethyl-5-methyl-2-[trans-4-(trifluoromethyl)cyclohexyl]pyrazolo[1,5-a]pyrimidin-7-yl}-3-methylpiperidin-1-yl]ethan-1-one,
1-{3-[5-methyl-6-(propan-2-yl)-2-[trans-4-(trifluoromethyl)cyclohexyl]pyrazolo[1,5-a]pyrimidin-7-yl]piperidin-1-yl}ethan-1-one,
1-[(3R)-3-methyl-3-{5-methyl-2-[trans-4-(trifluoromethyl)cyclohexyl]pyrazolo[1,5-a]pyrimidin-7-yl}piperidin-1-yl]ethan-1-one,
1-[(3S)-3-{6-ethyl-5-methyl-2-[trans-4-(trifluoromethyl)cyclohexyl]pyrazolo[1,5-a]pyrimidin-7-yl}piperidin-1-yl]ethan-1-one,
(3R)-3-{6-ethyl-5-methyl-2-[trans-4-(trifluoromethyl)cyclohexyl]pyrazolo[1,5-a]pyrimidin-7-yl}-1-methanesulfonyl-3-methylpiperidine,
methyl (3R,4S)-4-methyl-3-{5-methyl-2-[trans-4-(trifluoromethyl)cyclohexyl]pyrazolo[1,5-a]pyrimidin-7-yl}piperidine-1-carboxylate,
methyl (3S,4R)-4-methyl-3-{5-methyl-2-[trans-4-(trifluoromethyl)cyclohexyl]pyrazolo[1,5-a]pyrimidin-7-yl}piperidine-1-carboxylate,
trans-3-{5,6-dimethyl-2-[trans-4-(trifluoromethyl)cyclohexyl]pyrazolo[1,5-a]pyrimidin-7-yl}-4-methylpiperidine-1-carbaldehyde,
1-[trans-3-{6-ethyl-5-methyl-2-[trans-4-(trifluoromethyl)cyclohexyl]pyrazolo[1,5-a]pyrimidin-7-yl}-4-methylpiperidin-1-yl]ethan-1-one,
trans-4-methyl-3-{5-methyl-2-[trans-4-(trifluoromethyl)cyclohexyl]pyrazolo[1,5-a]pyrimidin-7-yl}piperidine-1-carbaldehyde,
methyl trans-3-{5,6-dimethyl-2-[trans-4-(trifluoromethyl)cyclohexyl]pyrazolo[1,5-a]pyrimidin-7-yl}-4-methylpiperidine-1-carboxylate,
5-{5,6-dimethyl-2-[trans-4-(trifluoromethyl)cyclohexyl]pyrazolo[1,5-a]pyrimidin-7-yl}-3,3-difluoropiperidine-1-carbaldehyde,
2-{6-ethyl-5-methyl-2-[trans-4-(trifluoromethyl)cyclohexyl]pyrazolo[1,5-a]pyrimidin-7-yl}morpholine-4-carbaldehyde,
methyl (2R)-2-{5-methyl-2-[trans-4-(trifluoromethyl)cyclohexyl]pyrazolo[1,5-a]pyrimidin-7-yl}morpholine-4-carboxylate,
methyl trans-2-methyl-3-{5-methyl-2-[trans-4-(trifluoromethyl)cyclohexyl]pyrazolo[1,5-a]pyrimidin-7-yl}piperidine-1-carboxylate,
(2R)-2-{5-methyl-2-[trans-4-(trifluoromethyl)cyclohexyl]pyrazolo[1,5-a]pyrimidin-7-yl}morpholine-4-sulfonamide,
methyl (2R,5S)-5-methyl-2-{5-methyl-2-[trans-4-(trifluoromethyl)cyclohexyl]pyrazolo[1,5-a]pyrimidin-7-yl}morpholine-4-carboxylate,
methyl (2R)-2-{3-fluoro-5-methyl-2-[trans-4-(trifluoromethyl)cyclohexyl]pyrazolo[1,5-a]pyrimidin-7-yl}morpholine-4-carboxylate,
5-methyl-7-[(3R)-oxan-3-yl]-2-[trans-4-(trifluoromethyl)cyclohexyl]pyrazolo[1,5-a]pyrimidine, and
5-methyl-7-[(3S)-oxan-3-yl]-2-[trans-4-(trifluoromethyl)cyclohexyl]pyrazolo[1,5-a]pyrimidine.

6 . A pharmaceutical composition comprising a therapeutically effective amount of a compound of formula (I) or pharmaceutically acceptable salts, biologically active metabolites, pro-drugs, racemates, enantiomers, diastereomers, solvates and hydrates thereof according to claim 1 as active ingredient and pharmaceutically acceptable carrier.

7 . A combination comprising a therapeutically effective amount of a compound of formula (I) or pharmaceutically acceptable salts, biologically active metabolites, pro-drugs, racemates, enantiomers, diastereomers, solvates and hydrates thereof according to claim 1 and one or more therapeutically active co-agents.

8 . A process for manufacturing pharmaceutical composition having GABA B receptor positive allosteric modulator effect characterized by mixing a therapeutically effective amount of a compound of formula (I) or pharmaceutically acceptable salts, biologically active metabolites, pro-drugs, racemates, enantiomers, diastereomers, solvates and hydrates thereof according to claim 1 and optical antipodes or racemates and/or salts thereof as active ingredients and pharmaceutically acceptable excipients.

9 . A compound of formula (I) or pharmaceutically acceptable salts, biologically active metabolites, pro-drugs, racemates, enantiomers, diastereomers, solvates and hydrates thereof according to claim 1 for use as GABA B receptor positive allosteric modulator.

10 . A compound of formula (I) or pharmaceutically acceptable salts, biologically active metabolites, pro-drugs, racemates, enantiomers, diastereomers, solvates and hydrates thereof according to claim 1 for use in the treatment or prevention of disorders associated with GABA B receptor positive allosteric modulator activity.

11 . The compound for use according to claim 10 wherein the disorder associated with GABA B receptor positive allosteric modulator activity is selected from the group of psychiatric disorders (such as anxiety, panic disorder, posttraumatic disorder, depression, schizophrenia), neurodevelopmental disorders (such as autism spectrum disorder, obsessive-compulsive disorder, Fragile X syndrome), cognitive disorders, epilepsy, spasticity, skeletal muscle rigidity, spinal cord injury, multiple sclerosis, amyotrophic lateral sclerosis, cerebral palsy, essential tremor, pain (neuropathic, visceral, osteoarthritic), substance abuse (cocaine, nicotine, alcohol), obesity, binge eating, asthma, cough, urinary incontinence, gastroesophageal reflux disease, transient lower esophageal sphincter relaxation, and irritable bowel syndrome

Assignees

• Richter Gedeon Nyrt

Inventors

• Borza István
• Éles János
• Román Viktor
• Petró József Levente
• Gegö Csaba Lehel
• BÉNYEI Gyula Attila

Classifications

• A61P25/18

  Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia · CPC title

• A61P19/02

  for joint disorders, e.g. arthritis, arthrosis · CPC title

• A61P25/32

  Alcohol-abuse · CPC title

• A61P11/06

  Antiasthmatics · CPC title

• A61P13/00

  Drugs for disorders of the urinary system · CPC title